Garcia-Saenz JA, Martinez-Janez N, Cubedo R, Jerez Y, Lahuerta A, Gonzalez-Santiago S, Ferrer N, Ramos M, Alonso-Romero JL, Anton A, Carrasco E, Chen J, Neuwirth R, Galinsky K, Vincent S, Leonard EJ, Slamon D. Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. Clin Cancer Res. 2022 Mar 15;28(6):1107-1116. doi: 10.1158/1078-0432.CCR-21-2652. PubMed PMID: 34980598; PubMed Central PMCID: PMC9365359.
AÑO: 2022; IF: 11.5